Concentra Group (CON) officer granted 40,000 RS; now owns 80,098

Q: What did Concentra Group (CON) report on this Form 4?

An officer received 40,000 restricted shares on 11/04/2025 at $0, vesting over four years.

Q: How many shares does the reporting person own after the transaction?

The reporting person beneficially owns 80,098 shares following the transaction.

Q: What is the vesting schedule for the restricted stock grant at CON?

The 40,000 restricted shares vest in equal annual installments over four years.

Q: What is the officer’s role noted in the filing for CON?

The officer is Executive Vice President, Chief Operating Officer Onsite Health & Telemedicine.

Q: What type of security was involved in the CON insider transaction?

Common stock (restricted stock) was granted; no derivative securities were listed in Table II.

Concentra Group Holdings Parent, Inc. (CON) reported a Form 4 showing an equity award to an executive.

Accepted by SEC EDGAR 11/06/2025 - 05:32 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Concentra Group Holdings Parent, Inc. (CON) reported a Form 4 showing an equity award to an executive. On 11/04/2025, the officer received 40,000 shares of restricted stock at $0. The grant will vest in equal annual installments over four years. After this transaction, the reporting person beneficially owned 80,098 shares, held directly. The executive’s title is Executive Vice President, Chief Operating Officer Onsite Health & Telemedicine.

Insider Trade Summary

Grant/Award: 40,000 shares

Grant/Award 1 txn

Insider Rhine Michael D.

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	40,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 80,098 shares (Direct)

Holdings Before and After: Common Stock, 40,098 to 80,098 shares (Direct)

Footnotes (1)

F1. Grant of restricted stock which will vest in equal annual installments over four years.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Concentra Group (CON) report on this Form 4?

An officer received 40,000 restricted shares on 11/04/2025 at $0, vesting over four years.

How many shares does the reporting person own after the transaction?

The reporting person beneficially owns 80,098 shares following the transaction.

What is the vesting schedule for the restricted stock grant at CON?

The 40,000 restricted shares vest in equal annual installments over four years.

What is the officer’s role noted in the filing for CON?

The officer is Executive Vice President, Chief Operating Officer Onsite Health & Telemedicine.

Was there a price paid for the awarded shares at CON?

The restricted stock was reported at a $0 price, consistent with equity grants.

What type of security was involved in the CON insider transaction?

Common stock (restricted stock) was granted; no derivative securities were listed in Table II.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rhine Michael D.

(Last)

(First)

(Middle)

C/O CONCENTRA GROUP HOLDINGS PARENT, INC

5080 SPECTRUM DRIVE, SUITE 1200W

(Street)

ADDISON

75001

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Concentra Group Holdings Parent, Inc. [ CON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/04/2025		A⁽¹⁾		40,000	A	$0	80,098	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Grant of restricted stock which will vest in equal annual installments over four years.

Remarks:

Executive Vice President, Chief Operating Officer Onsite Health & Telemedicine

	/s/ Timothy F. Ryan, Attorney-in-Fact	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR